CG 806

Drug Profile

CG 806

Alternative Names: CG 026806; CG’806

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CrystalGenomics
  • Developer Aptose Biosciences; CrystalGenomics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 10 Jul 2018 Aptose Biosciences has patent protection for CG 806 in Japan
  • 19 Jun 2018 Pharmacodynamics and adverse event data from in vitro studies presented at the 23rd Congress of the European Hematology Association (EHA-2018)
  • 14 Jun 2018 Aptose Biosciences extends licensing agreement with CrystalGenomics to develop and commercialise CG 806 in China, Hong Kong, Macau.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top